About US
Contact us
-
Yin Li meets Deputy Director General of New Zealand Ministry for Primary IndustriesOn the afternoon of April 16, 2013, Yin Li met with Ms. Carole Barnao, Deputy Director General of New Zealand Ministry for Primary Industries, and her entourage. Both sides introduced the main respons2013/4/19
-
Supreme Court exposes GlaxoSmithKline to Humana's Avandia-spending claimsThe U.S. Supreme Court declined to consider an appeal from GlaxoSmithKline ($GSK) in a fight over Humana's spending on the company's disgraced diabetes drug Avandia. The ruling not only opens GSK t2013/4/17
-
FDA puts halt to generic OxyContinFor months FDA regulators have been wrestling with the dangers of allowing a flood of cheap, generic versions of the highly addictive OxyContin on the market versus the benefit of consumers with pa2013/4/17
-
AbbVie to hack hundreds of reps from cardiovascular sales ranksAbbVie ($ABBV) has a new distinction. It may be the youngest pharma company ever to lay off hundreds of salespeople. Bloomberg reports that the drugmaker, spun off by Abbott Laboratories ($ABT) as2013/4/16
-
CFDA Commissioner Zhang Yong meets the delegation of Swedish Ministry of Health and Social AffairsOn the morning of April 16, 2013, Zhang Yong, Commissioner of China Food and Drug Administration (CFDA), met with the delegation led by Mr. Goran Hagglund, the Swedish Minister for Health and Social2013/4/16
-
2013 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 2nd station--Xian was successfully concluded2013 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 2nd station--Xian , was successfully concluded on 11 April at Xian Enlite Hotel. Around 100 technical persons from 26 pha2013/4/15
-
Roche CEO says no need to buy out Japanese subsidiary ChugaiWhen it comes to its investment in Japan's Chugai Pharmaceutical, Roche CEO Severin Schwan says he likes things just the way they are. "We don't see changes in the structural set-up ... currency fluct2013/4/15
-
Pfizer cuts physician payments by about $17M in 2012It's not that there is no free lunch for doctors, there are just fewer of them. Some members of Big Pharma are significantly cutting their budgets for spending on docs as lost sales and resulting d2013/4/15
-
Pfizer Ventures backs effort to amp up orphan-drug developmentDavid Mott, ex-CEO of MedImmune and a high-profile biotech partner at New Enterprise Associates, has led the way toward an orphan drug accelerator also backed by Pfizer Ventures. The Cambridge, MA-ba2013/4/12
-
Eli Lilly to lay off hundreds in sales as Cymbalta nears edge of patent cliffHere is a business reality that hundreds of Eli Lilly ($LLY) sales employees are going to have to align themselves with quite soon: They are about to lose their jobs. With its best-selling drug, th2013/4/12